Dr. Iqbal has cared for Mr. Jenkins for several years. Mr. Jenkins had been diagnosed with cancer of the prostate two years ago. A nearby teaching hospital contacted Dr. Iqbal to see if Mr. Jenkins would consent to participating in a randomized clinical trial. If Mr. Jenkins entered the trial he would be placed in either the standard treatment (control) group or the group given an experimental combination of potent new agents. The standard treatment posed only minor risks, but, unfortunately, offered only modest benefits. Two-year survival rates were as low as 3%. The experimental agent was more promising. Preliminary data showed better two-year survival rates (than the standard treatment), perhaps ten times greater. Unfortunately, the side-effects were also greater by about ten times as bad as the standard treatment. Would Mr. Jenkins be participating in a therapeutic or non-therapeutic research protocol